Our Products
Our Products

About OBS

OBS Group (“OBS”) is one of the Pakistan’s leading corporations in the healthcare segment with a strong presence in Pakistan and Sri Lanka. OBS commenced operations in 1963 and became a name associated with quality medicine throughout Pakistan in 2006 after entering into a strategic alliance with Organon (part of Akzo Nobel). Since then, OBS has fostered strategic alliances with many reputable international firms including Organon, Merck & Co Inc, USA, Schering Plough, AstraZeneca, Mylan USA, Vifor and Santen Pharma Japan.

 

At present, OBS ranks amongst the top 10 pharmaceutical players in Pakistan with a group turnover in excess of PKR 9,300 million and profits of over PKR 2,000 mn with professionally trained medical representatives covering more than 20,000 healthcare professionals across the country.

 

The key focus areas of OBS include Anti-Infectives, Cardiology, CNS, Diabetes & Metabolic Disorders, Gastroenterology, Ophthalmology, Respiratory, Women Health (Infertility, HRT & Contraception) and Vaccines. OBS  has 106 pharmaceutical and 7 consumer brands in Pakistan and 12 pharmaceutical brands in Sri Lanka and a strong presence in Afghanistan. The OBS  is now looking to tap markets in Vietnam and Uzbekistan with various products which are under registration.

OBS group operates in Pakistan via its sister concerns:

 

  • OBS Healthcare (Pvt.) Limited (Formerly Organon Pakistan)
  • OBS Ophthalmics (Pvt.) Limited (Formerly OBS Pharma (Pvt.) Limited)
  • OBS Pakistan (Pvt.) Limited (Formerly Merck Sharp & Dohme of Pakistan)
  • AGP Limited
  • Aspin Pharma (Pvt) Limited (Formerly Janssen Pharmaceuticals – Johnson & Johnson)